Literature DB >> 2228458

Searching for consensus through multi-criteria decision analysis. Assessment of screening strategies for hemoglobinopathies in southeastern France.

C Le Gales, J P Moatti.   

Abstract

Until now, no systematic strategy for the prevention of major hemoglobinopathies has been implemented in southeastern France, in spite of frequencies of beta-thalassemia trait and HbS trait as high as 2.5-8% in some ethnic populations. The purpose of the study was to help a group of experts, brought together by the Regional Center for Disease Control, to reach a consensus about screening for carriers of heterozygote hemoglobinopathies. A multicriteria decision-analysis model was used to take into account not only the costs and effectiveness of potential screening strategies, but also five other qualitative criteria: technical and practical feasibilities, ethical acceptability, information follow-up in time, and global impact on health education. Conclusions differ significantly from those of a pure cost-effectiveness analysis, but a multicriteria approach seems best suited to medical experts' preferences.

Entities:  

Mesh:

Year:  1990        PMID: 2228458     DOI: 10.1017/s0266462300001033

Source DB:  PubMed          Journal:  Int J Technol Assess Health Care        ISSN: 0266-4623            Impact factor:   2.188


  7 in total

Review 1.  Assessing the value of healthcare interventions using multi-criteria decision analysis: a review of the literature.

Authors:  Kevin Marsh; Tereza Lanitis; David Neasham; Panagiotis Orfanos; Jaime Caro
Journal:  Pharmacoeconomics       Date:  2014-04       Impact factor: 4.981

2.  Assessing the Preferences for Criteria in Multi-Criteria Decision Analysis in Treatments for Rare Diseases.

Authors:  Carina Schey; Maarten Jacobus Postma; Paul F M Krabbe; Olekdandr Topachevskyi; Andrew Volovyk; Mark Connolly
Journal:  Front Public Health       Date:  2020-05-08

Review 3.  Organizational aspect in healthcare decision-making: a literature review.

Authors:  Amélie Dubromel; Marie-Audrey Duvinage-Vonesch; Loïc Geffroy; Claude Dussart
Journal:  J Mark Access Health Policy       Date:  2020-08-31

Review 4.  Assessing the value of orphan drugs using conventional cost-effectiveness analysis: Is it fit for purpose?

Authors:  Maarten J Postma; Declan Noone; Mark H Rozenbaum; John A Carter; Marc F Botteman; Elisabeth Fenwick; Louis P Garrison
Journal:  Orphanet J Rare Dis       Date:  2022-04-05       Impact factor: 4.123

Review 5.  Evidence and Value: Impact on DEcisionMaking--the EVIDEM framework and potential applications.

Authors:  Mireille M Goetghebeur; Monika Wagner; Hanane Khoury; Randy J Levitt; Lonny J Erickson; Donna Rindress
Journal:  BMC Health Serv Res       Date:  2008-12-22       Impact factor: 2.655

Review 6.  Balancing costs and benefits at different stages of medical innovation: a systematic review of Multi-criteria decision analysis (MCDA).

Authors:  Philip Wahlster; Mireille Goetghebeur; Christine Kriza; Charlotte Niederländer; Peter Kolominsky-Rabas
Journal:  BMC Health Serv Res       Date:  2015-07-09       Impact factor: 2.655

7.  Comprehensive value assessment of drugs using a multi-criteria decision analysis: An example of targeted therapies for metastatic colorectal cancer treatment.

Authors:  Jason C Hsu; Jia-Yu Lin; Peng-Chan Lin; Yang-Cheng Lee
Journal:  PLoS One       Date:  2019-12-12       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.